Sanofi India Q2 FY26: Net sales up 6%, PBT jumps 19%

Exceptional ItemEbitda Margin ExpansionResults View source PDF Explain this filing

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹3395.00

prior close

₹3411.20

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-3.5% vs market

Pharmaceuticals peers, median of 165sector-0.0%-2.2% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-2.5

15m

-2.1

30m

-1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2+1.3-3.5-0.0-2.2

Next day

-1.2+1.6-2.8+0.2-1.4

-1.3+1.7-3.0+0.4-1.7

-1.9+1.6-3.5+1.1-3.0

-2.8+1.5-4.2+1.2-4.0

-4.8+1.8-6.6+1.0-5.8

-4.7+2.1-6.8+0.5-5.2

15d

-6.1+3.2-9.2+0.2-6.2

-8.1+3.7-11.8+1.7-9.8

-11.0+1.1-12.2+1.2-12.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi India Q2 FY26 (quarter ended June 30, 2026): Revenue from operations grew 8 percent YoY domestically to Rs 437.7 crore. Profit before tax rose 19 percent to Rs 112.3 crore versus Rs 94.1 crore. Diabetes portfolio grew 14 percent, with 58 percent value market share. PBT margin improved to 27 percent from 24 percent, aided by 5 percent lower operating expenses. Q2 PAT was Rs 83.5 crore (EPS Rs 36.26). CFO Rachid Ayari steps down effective Sept 30, 2026.

Likely market impact

Strong Q2 with margin expansion and double-digit diabetes growth signals healthy business momentum. CFO exit may create short-term leadership uncertainty.